Defining the role of histone deacetylases in the inhibition of mammary carcinogenesis by dietary energy restriction (DER): Effects of suberoylanilide hydroxamic acid (SAHA) and DER in a rat model

Cancer Prevention Research

Volumn 6, Issue 4, 2013, Pages 290-298

  Zhu, Zongjian ^a   Jiang, Weiqin ^a   McGinley, John N ^a   Thompson, Henry J ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; HISTONE H2A; HISTONE H2B; HISTONE H3; HISTONE H4; METHYLNITROSOUREA; PROTEIN P53; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CALORIC RESTRICTION; CANCER INHIBITION; CONTROLLED STUDY; DEACETYLATION; FEMALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALORIC RESTRICTION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; METHYLNITROSOUREA; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84877267617     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0449-T     Document Type: Article

References (46)

1. Thompson HJ, McTiernan A. Weight cycling and cancer: weighing the evidence of intermittent caloric restriction and cancer risk. Cancer Prev Res 2011;4:1736-42.
2. Hursting SD, Smith SM, Lashinger LM, Harvey AE, Perkins SN. Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. Carcinogenesis 2010;31:83-9.
3. Thompson HJ, Jiang W, Zhu Z. Energetics and cancer: exploring a road less traveled. In: New York, NY: McTiernan A, editor. Physical activity, dietary calorie restriction, and cancer. 1st ed. Springer Science + Business Media, LLC; 2011. p. 55-67.
4. International Agency for Research on Cancer. Physical activity, weight control, and cancer. In: Vainio H, Bianchin IF, editors. Cancer prevention handbook. Lyon, France: IARC Press; 2002.
5. World Cancer Research Fund, American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
6. Zhu Z, Haegele AD, Thompson HJ. Effect of caloric restriction on pre-malignant and malignant stages of mammary carcinogenesis. Carcinogenesis 1997;18:1007-12. (Pubitemid 28132347)
7. Jiang W, Zhu Z, Thompson HJ. Effect of energy restriction on cell cycle machinery in 1-methyl-1-nitrosourea-induced mammary carcinomas in rats. Cancer Res 2003;63:1228-34. (Pubitemid 36348699)
8. Thompson HJ, Zhu Z, Jiang W. Identification of the apoptosis activation cascade induced in mammary carcinomas by energy restriction. Cancer Res 2004;64:1541-5. (Pubitemid 38235628)
9. Zhu Z, Jiang W, McGinley J, Wolfe P, Thompson HJ. Effects of dietary energy repletion and IGF-1 infusion on the inhibition of mammary carcinogenesis by dietary energy restriction. Mol Carcinog 2005;42: 170-6. (Pubitemid 40271146)
10. Jiang W, Zhu Z, Thompson HJ. Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. Cancer Res 2008;68:5492-9.
11. Alers S, Loffler AS, Wesselborg S, Stork B. Role of AMPK-mTOR-Ulk1/2 in the regulation of autophagy: cross talk, shortcuts, and feedbacks. Mol Cell Biol 2012;32:2-11.
12. Kwon HS, Ott M. The ups and downs of SIRT1. Trends Biochem Sci 2008;33:517-25.
13. Baur JA, Chen D, Chini EN, Chua K, Cohen HY, de CR, et al. Dietary restriction: standing up for sirtuins. Science 2010;329:1012-3.
14. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000;92:1210-6. (Pubitemid 30627729)
15. Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res 2009;69:1702-5.
16. Liu T, Kuljaca S, Tee A, Marshall GM. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat Rev 2006;32:157-65.
17. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de CR. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov 2012;11:443-61.
18. Ma X, Ezzeldin HH, Diasio RB. Histone deacetylase inhibitors: current status and overview of recent clinical trials. Drugs 2009;69:1911-34.
19. Stunkel W, Campbell RM. Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen 2011;16:1153-69.
20. Cellai C, Balliu M, Laurenzana A, Guandalini L, Matucci R, Miniati D, et al. The new low-toxic histone deacetylase inhibitor S-(2) induces apoptosis in various acute myeloid leukaemia cells. J Cell Mol Med 2012;16:1758-65.
21. Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 2008;153:657-68. (Pubitemid 351271755)
22. Kyrylenko S, Kyrylenko O, Suuronen T, Salminen A. Differential regulation of the Sir2 histone deacetylase gene family by inhibitors of class I and II histone deacetylases. Cell Mol Life Sc 2003;60:1990-7. (Pubitemid 37222594)
23. Cohen LA, Amin S, Marks PA, Rifkind RA, Desai D, Richon VM. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA). Anticancer Res 1999;19:4999-5005. (Pubitemid 30103315)
24. Cohen LA, Marks PA, Rifkind RA, Amin S, Desai D, Pittman B, et al. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors. Anticancer Res 2002;22:1497-504. (Pubitemid 34839156)
25. Thompson HJ, McGinley JN, Rothhammer K, Singh M. Rapid induction of mammary intraductal proliferations, ductal carcinoma in situ and carcinomas by the injection of sexually immature female rats with 1-methyl-1-nitrosourea. Carcinogenesis 1995;16:2407-11.
26. Singh M, McGinley JN, Thompson HJ. A comparison of the histopathology of premalignant and malignant mammary gland lesions induced in sexually immature rats with those occurring in the human. Lab Invest 2000;80:221-31. (Pubitemid 30120974)
27. Thompson HJ, Singh M, McGinley J. Classification of premalignant and malignant lesions developing in the rat mammary gland after injection of sexually immature rats with 1-methyl-1-nitrosourea. J Mammary Gland Biol Neoplasia 2000;5:201-10. (Pubitemid 32045696)
28. Zhu Z, Jiang W, McGinley JN, Prokopczyk B, Richie JP Jr, El BK, et al. Mammary gland density predicts the cancer inhibitory activity of the N-3 to N-6 ratio of dietary fat. Cancer Prev Res 2011;4:1675-85.
29. Snedecor GW, Cochran WG. Statistical methods. 8th ed. Ames, IA: Iowa State University Press; 1989.
30. Sokal RR, Rohlf FJ. Biometry the principles and practice of statistics in biological research. 3rd ed. New York: W.H. Freeman; 1995.
31. Huh MH, Critchlow DE, Verducci JS, Kiecolt-Glaser J, Glaser R, Malarkey WB. A symmetric analysis of paired rankings with application to temporal patterns of hormonal concentration. Biometrics 1995;51: 1361-71. (Pubitemid 26030181)
32. Collett D. Modelling survival data in medical research. London, UK: Chapman and Hall; 1994.
33. Morrison DF. Multivariate statistical methods. 3rd ed. New York: McGraw-Hill Publishing Co.; 1990.
34. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976;36:2699-702.
35. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;35:1332-8.
36. Li D, Marchenko ND, Moll UM. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 2011;18: 1904-13.
37. Fortson WS, Kayarthodi S, Fujimura Y, Xu H, Matthews R, Grizzle WE, et al. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells. Int J Oncol 2011;39:111-9.
38. Uo T, Veenstra TD, Morrison RS. Histone deacetylase inhibitors prevent p53-dependent and p53-independent Bax-mediated neuronal apoptosis through two distinct mechanisms. J Neurosci 2009;29: 2824-32.
39. Pollak M. Do cancer cells care if their host is hungry? Cell Metab 2009;9:401-3.
40. Chu F, Chou P, Mirkin BL, Mousa SA, Rebbaa A. Cellular conditioning with trichostatin A enhances the anti-stress response through up-regulation of HDAC4 and down-regulation of the IGF/Akt pathway. Aging Cell 2008;7:516-25. (Pubitemid 351998612)
41. Zhu Z, Jiang W, McGinley JN, Thompson HJ. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res 2005;65: 7023-30. (Pubitemid 41060743)
42. Efeyan A, Sabatini DM. mTOR and cancer: many loops in onepathway. Curr Opin Cell Biol 2010;22:169-76.
43. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12:21-35.
44. McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer 2010;10 Suppl 3: S59-65.
45. She QB, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008;3:e3065.
46. Keel PK, Baxter MG, Heatherton TF, Joiner TE Jr. A 20-year longitudinal study of body weight, dieting, and eating disorder symptoms. J Abnorm Psychol 2007;116:422-32. (Pubitemid 46800352)